Keyphrases
Melanin
100%
Structure Function
100%
Fungal Melanin
100%
Therapeutic Efficacy
100%
Melanoma
100%
Radioimmunotherapy
100%
Hydrophobic Interaction
40%
188Re
40%
Metastatic Melanoma
40%
New Drugs
20%
Difficult-to-treat
20%
Humanization
20%
Antibody Binding
20%
Negatively Charged
20%
Phase I Clinical Trial
20%
Further Development
20%
Stage III-IV
20%
Melanin Binding
20%
B16F10
20%
Monoclonal IgM
20%
CTLA-4 Inhibitors
20%
Comparative Structural Analysis
20%
Positively Charged Amino Acid
20%
213Bi
20%
Murine Melanoma
20%
Binding Surface
20%
Charge Interaction
20%
Murine Melanoma Model
20%
In Vivo Data
20%
Cyclic GMP
20%
Anti-CTLA-4
20%
Aromatic Residues
20%
Medicine and Dentistry
Melanin
100%
Combination Therapy
100%
Radioimmunotherapy
100%
Melanoma
100%
Immunoglobulin M
28%
Rhenium 188
28%
Metastatic Melanoma
28%
Clinical Trial
14%
Immunotherapy
14%
Amino Acid
14%
Cytotoxic T Lymphocyte Antigen 4 Antibody
14%
Peptide Sequence
14%
Bismuth 213
14%
Pharmacology, Toxicology and Pharmaceutical Science
Combination Therapy
100%
Melanin
100%
Melanoma
100%
Immunoglobulin M
28%
Murine
28%
Metastatic Melanoma
28%
Rhenium 188
28%
Clinical Trial
14%
Immunotherapy
14%
Amino Acid
14%
Good Manufacturing Practice
14%
Bismuth 213
14%
Cytotoxic T Lymphocyte Antigen 4 Antibody
14%
Cytotoxic T Lymphocyte Antigen 4
14%
Immunology and Microbiology
Immunoglobulin M
100%
Murine
100%
Immunotherapy
50%
Amino Acid Sequence
50%
Amino Acid
50%
Binding Antibody
50%
Cytotoxic T Lymphocyte Antigen 4 Antibody
50%